本文選題：非小細胞肺癌 + RSK4　； 參考：《桂林醫(yī)學院》2017年碩士論文

【摘要】：目的:肺癌是目前全世界癌癥相關死亡的首要原因。非小細胞肺癌(non-small cell lung cancer,NSCLC)是肺癌亞型中最常見的類型。核糖體S6蛋白激酶4(ribosomal S6 kinase 4,RSK4)作為一個蛋白激酶調(diào)節(jié)細胞生長、遷移、增殖和存活。其在肺癌中的表達及意義尚不明確。本研究通過免疫組織化學和RT-PCR檢測非小細胞肺癌組織中RSK4蛋白和mRNA,探討其在非小細胞肺癌與癌旁非瘤組織中的表達差異、其表達與臨床病理特征的關系。闡明RSK4在非小細胞肺癌組織中的表達及意義。方法:選取40例2015年01月到2015年12月本院就診的NSCLC患者納入研究。所有的納入研究的患者均經(jīng)病理科確診為NSCLC,并在實驗前由3位中級以上病理科醫(yī)師復診無疑義者。RSK4 mRNA和蛋白分別用RT-PCR和免疫組織化學法進行檢測。所有用于RT-PCR的肺癌組織標本和癌旁非瘤組織標本均在手術中獲取;對應的石蠟組織標本從病理科獲得。并將RSK4基因的表達水平與患者的臨床病理特征進行比較。結果:與癌旁非瘤肺組織比較,RSK4 mRNA及蛋白在NSCLC組織中的表達下調(diào)(P0.01)。同時,RSK4蛋白在NSCLC組織中的含量也明顯低于肺大皰患者的肺組織(P0.01)。RSK4表達下調(diào)與NSCLC的腫瘤大小、TNM分期相關;而與年齡、性別、CEA水平、腺癌或鱗癌的組織學類型無關。結論:RSK4在NSCLC中表達下調(diào),與腫瘤大小、臨床病理分期有關,提示RSK4在NSCLC中可能發(fā)揮抑癌基因的功能。
[Abstract]:Objective: lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer. Ribosomal S6 protein kinase (4(ribosomal S6 kinase 4 RSK4) acts as a protein kinase to regulate cell growth, migration, proliferation and survival. Its expression and significance in lung cancer is unclear. In this study, the expression of RSK4 protein and mRNAs in non-small cell lung cancer (NSCLC) tissues were detected by immunohistochemistry and RT-PCR, and the expression of RSK4 protein and mRNAs in non-small cell lung cancer (NSCLC) and adjacent non-tumor tissues (NSCLC) was studied. To elucidate the expression and significance of RSK4 in non-small cell lung cancer (NSCLC). Methods: 40 NSCLC patients from January 2015 to December 2015 were included in the study. All the patients included in the study were diagnosed as NSCLC by pathology, and the mRNA and protein of RSK4 were detected by RT-PCR and immunohistochemistry respectively. All lung cancer tissue specimens and adjacent non-tumor specimens were obtained during operation, and the corresponding paraffin tissues were obtained from pathologists. The expression level of RSK4 gene was compared with the clinicopathological features of the patients. Results: the expression of RSK4 mRNA and protein was down-regulated in NSCLC tissues compared with non-cancerous lung tissues. At the same time, the expression of RSK4 protein in NSCLC was significantly lower than that in patients with bullous lung. The down-regulated expression of RSK4 was correlated with the tumor size and TNM stage of NSCLC, but not with age, sex and CEA level, histological type of adenocarcinoma or squamous cell carcinoma. Conclusion the down-regulation of the expression of RSK4 in NSCLC is related to tumor size and clinicopathologic stage, suggesting that RSK4 may play a role as a tumor suppressor gene in NSCLC.
【學位授予單位】：桂林醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2

【參考文獻】

相關期刊論文 前7條

1 劉瀟衍;李峻嶺;;晚期非小細胞肺癌的治療選擇[J];中國腫瘤臨床;2015年19期

2 金靜思;賀巾釗;周黎明;;非小細胞肺癌分子靶向治療藥物的現(xiàn)狀及進展[J];中國腫瘤臨床;2015年17期

3 劉鵬飛;張會來;;精準醫(yī)療在非小細胞肺癌中的應用[J];國際生物醫(yī)學工程雜志;2015年04期

4 郭永軍;;非小細胞肺癌靶向基因研究新進展[J];河南醫(yī)學研究;2015年02期

5 蔡君;張濤;;RSK4蛋白在結直腸癌中的表達及臨床意義[J];腫瘤學雜志;2015年03期

6 田聰;湯麗娜;祁偉祥;林峰;李洪濤;姚陽;;多靶點受體酪氨酸激酶抑制劑聯(lián)合化療治療晚期非小細胞肺癌的Meta分析[J];腫瘤;2013年09期

7 田艷;田中;吳柯;胡光欣;趙停婷;鐘朝暉;;恩度聯(lián)合含鉑類化療藥物治療晚期非小細胞肺癌的療效及安全性的Meta分析[J];重慶醫(yī)科大學學報;2012年02期

，

本文編號：2049490